We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Easy and Cost-Effective Production of Functional siRNA Achieved with Generation Kit

By LabMedica International staff writers
Posted on 26 May 2010
A siRNA generation kit enables easy and cost-effective generation of a large number of small interfering RNAs (siRNAs) from full-length target genes.

siRNAs are 21-23-nucleotide RNA molecules that can cause targeted gene silencing in mammalian cells through a process known as RNA interference. More...
In nature, siRNAs are generated by ribonuclease III cleavage of longer double-stranded RNAs (dsRNAs). When dsRNAs are transfected directly into mammalian cells, they activate the interferon system and provoke nonspecific gene suppression and cytotoxic response. siRNAs have proven to be effective at specifically silencing gene expression without causing any interferon response.

Using an ultra-active form of human recombinant dicer enzyme, a double-stranded RNA-specific endonuclease, it is possible using the kit to cleave more than 95% of dsRNA template into 22 bp [base pair] siRNAs within two hours under optimized reaction conditions. In contrast to individual synthetic siRNAs, the Turbo Dicer kit allows the user to quickly produce multiple siRNA species against the target mitochondrial RNA (mRNA), and thereby achieve effective gene silencing with minimal guesswork. Moreover, due to the minimal concentration of any individual siRNA species generated with the Turbo Dicer enzyme, off-target effects are not a problem.

For maximum convenience, the Turbo Dicer siRNA generation kit, developed by from Amsbio (Abingdon, UK), contains everything that is required for preparing double-stranded RNA from the user's target gene(s), dsRNA cleavage, siRNA cleanup, and transfection. Both the Recombinant Turbo Dicer enzyme and the RNA purification columns are also available separately.

AMS Biotechnology (Amsbio) is a leading international provider of products and custom services for life sciences research. The company's range includes over 23,000 polyclonal and monoclonal antibodies, peptides, recombinant proteins, extracellular matrix, molecular detection reagents, tissue DNA, RNA, protein, and microarray products. Key research areas include apoptosis, cell invasion and migration, cell signaling, DNA damage, electrophoresis, glycobiology, posttranslational modification, and stem cell biology.

Related Links:
Amsbio



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.